South Korea’s Celltrion Healthcare (Kosdaq: 068270) saw its shares gain more than 3% to 275,500 won today, after it revealed over the weekend that the Korean Ministry of Food and Drug Safety (MFDS) approved its regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19.
The drug is indicated for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19.
This marks the first time a monoclonal antibody (MAb) treatment for COVID-19 has received a full approval to treat patients with COVID-19 from the Korean MFDS.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze